RxDoctor Payments Data

John Nguyen, MD

Ophthalmic Plastic and Reconstructive Surgery · Morgantown, WVNPI 1457556003

Payments from drug & device makers

$713,663in general payments, 2019–2025

Across 278 payments — averaging $2567.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$625K
  • Argenx US, Inc.$32K
  • Kerecis Limited$19K
  • ANI Pharmaceuticals, Inc.$18K
  • Genentech, Inc.$18K
  • Biotissue Holdings Inc.$231
  • plus $935 from 11 others

What the payments were for

  • Consulting fees$8,3505%
  • Speaking & faculty fees$124,49075%
  • Travel & lodging$22,26213%
  • Food & beverage$8,5815%
  • Education$3,0102%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$157,046
Medicare patients
369
Services billed
852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TepezzaTeprotumumab-Trbw33$1,858,267
ErythromycinErythromycin Base276$3,153
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha116$1,237
Cephalexin81$634
Doxycycline Hyclate33$394
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$155
Clindamycin Hcl11$111
Sodium Chloride0.9 % Sodium Chloride34$94
Methylprednisolone12$51
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenTepezza$624,890$1,858,26733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few ophthalmic plastic and reconstructive surgery providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other ophthalmic plastic and reconstructive surgery in Morgantown

Where these figures come from

Is this you, or does something look wrong? →